HomeCOH • ASX
Cochlear Ltd
$281.41
Sep 27, 7:00:00 PM GMT+10 · AUD · ASX · Disclaimer
StockAU listed securityAU headquartered
Previous close
$284.21
Day range
$281.01 - $284.99
Year range
$237.69 - $350.31
Market cap
18.43B AUD
Avg Volume
199.23K
P/E ratio
51.83
Dividend yield
1.46%
Primary exchange
ASX
Financials
Income Statement
Revenue
Net income
(AUD)Jun 2024Y/Y change
Revenue
568.55M8.20%
Operating expense
305.05M5.74%
Net income
82.70M4.03%
Net profit margin
14.55-3.83%
Earnings per share
——
EBITDA
126.20M16.26%
Effective tax rate
26.42%—
Total assets
Total liabilities
(AUD)Jun 2024Y/Y change
Cash and short-term investments
513.60M-7.54%
Total assets
2.75B6.87%
Total liabilities
904.60M10.33%
Total equity
1.84B—
Shares outstanding
65.49M—
Price to book
10.11—
Return on assets
11.42%—
Return on capital
15.04%—
Net change in cash
(AUD)Jun 2024Y/Y change
Net income
82.70M4.03%
Cash from operations
115.85M-15.22%
Cash from investing
-28.95M-44.39%
Cash from financing
-73.20M26.69%
Net change in cash
14.20M-15.98%
Free cash flow
83.96M23.15%
About
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015. Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
Founded
1981
Employees
5,047
Search
Clear search
Close search
Google apps
Main menu